These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 938829)

  • 21. [Endolymphatic radionuclide therapy. Historical development and present status].
    Makoski HB; Magnus L; Scherer E; Stauch GW; Strötges MW
    Dtsch Med Wochenschr; 1973 Nov; 98(46):2207-13. PubMed ID: 4593334
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytotoxic and genotoxic effect of the [166Dy]Dy/166Ho-EDTMP in vivo generator system in mice.
    Pedraza-López M; Ferro-Flores G; Arteaga de Murphy C; Morales-Ramírez P; Piedras-Ross J; Murphy-Stack E; Hernández-Oviedo O
    Nucl Med Biol; 2004 Nov; 31(8):1079-85. PubMed ID: 15607490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer.
    Amdur RJ; Dan T; Mazzaferri E
    Am J Clin Oncol; 2013 Aug; 36(4):348-53. PubMed ID: 22547013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
    Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
    J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Busulfan versus 32P in polycythaemia vera.
    Zittoun R
    Drugs Exp Clin Res; 1986; 12(1-3):283-5. PubMed ID: 3525077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone marrow dosimetry: regional variability of marrow-localizing antibody.
    Sgouros G; Jureidini IM; Scott AM; Graham MC; Larson SM; Scheinberg DA
    J Nucl Med; 1996 Apr; 37(4):695-8. PubMed ID: 8691269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of the linear-quadratic model to radioimmunotherapy: further support for the advantage of longer-lived radionuclides.
    Howell RW; Goddu SM; Rao DV
    J Nucl Med; 1994 Nov; 35(11):1861-9. PubMed ID: 7965170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
    J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative evaluation of bone marrow hematopoiesis in the sternum and ilium of dogs after total nonuniform x-ray irradiation].
    Kalandarova MP
    Radiobiologiia; 1979; 19(2):214-9. PubMed ID: 472151
    [No Abstract]   [Full Text] [Related]  

  • 31. [Dosimetry of the hematopoietic system in radioiodine therapy of thyroid cancer].
    Günter HH; Junker D; Schober O; Hundeshagen H
    Strahlenther Onkol; 1987 Mar; 163(3):185-91. PubMed ID: 3563879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N
    J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton.
    Bolch WE; Patton PW; Rajon DA; Shah AP; Jokisch DW; Inglis BA
    J Nucl Med; 2002 Jan; 43(1):97-108. PubMed ID: 11801712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haematological complications in polycythaemia vera and thrombocythaemia patients treated with radiophosphorus (32P).
    Randi ML; Fabris F; Varotto L; Rossi C; Macri C; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(3):461-7. PubMed ID: 1703118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Radioembolization with 32P-labelled glass microspheres for advanced hepatocellular carcinoma].
    Yan L; Li L; Chen S
    Zhonghua Wai Ke Za Zhi; 1996 Sep; 34(9):526-9. PubMed ID: 9594154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycophorin A as a biological dosimeter for radiation dose to the bone marrow from iodine-131.
    Jensen RH; Reynolds JC; Robbins J; Bigbee WL; Grant SG; Langlois RG; Pineda JD; Lee T; Barker WC
    Radiat Res; 1997 Jun; 147(6):747-52. PubMed ID: 9189175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of different doses of 32P in the treatment of primary thrombocytosis.
    Randi ML; Fabris F; Varotto L; Peverelli P; Girolami A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(6):950-6. PubMed ID: 2419226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On thorotrast leucaemia. Evolution of clone of bone marrow cells with radiation-induced chromosome aberrations.
    Visfeldt J; Jensen G; Hippe E
    Acta Pathol Microbiol Scand A; 1975 Jul; 83(4):373-8. PubMed ID: 1057367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
    Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.
    Leichner PK; Rosenshein NB; Leibel SA; Order SE
    Radiology; 1980 Mar; 134(3):729-34. PubMed ID: 7355227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.